Syndax Pharmaceuticals Stock News

Credit Suisse AG reduced its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 7.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,945 shares of the companys stock after selling 1,948 shares during the period. Credit Suisse AGs [] The post Credit Suisse AG Sells 1,948 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) appeared first on ETF Daily News .

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.46% to the previous days close as strong demand from buyers drove the stock to $16.83. Actively observing the price movement in the last trading, the stock closed the session at $17.08, falling within a range of $16.60 Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Stock Seems Like A Good Option Read More »

Charles Schwab Investment Management Inc. increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 16.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 269,631 shares of the companys stock after purchasing an additional 38,698 shares during the period. Charles Schwab Investment Management Inc.s []

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Equities research analysts at B. Riley boosted their FY2021 earnings estimates for Syndax Pharmaceuticals in a note issued to investors on Wednesday, November 17th. B. Riley analyst J. Walsh now anticipates that the company will post earnings of ($2.11) per share for the year, up from their prior forecast of []

Syndax Pharmaceuticals (NASDAQ:SNDX) released its quarterly earnings data on Monday. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.24, MarketWatch Earnings reports. Syndax Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 6,031.18%. During the same quarter in the previous year, the []

WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call Transcript

Wall Street brokerages predict that Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) will announce earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Syndax Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($0.65). Syndax Pharmaceuticals reported []

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's

The stock price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) increased by over 14% today. This is why it happened.